GO:0031638 zymogen activation: Mechanism, Genes and Research

Zymogen activation (GO:0031638) is a fundamental biological process in which an inactive enzyme precursor, called a zymogen or proenzyme, is converted into a catalytically active enzyme through proteolytic cleavage. This mechanism is critical for regulating proteases that would otherwise cause uncontrolled protein degradation or signaling if active constitutively. Zymogens are synthesized with an inhibitory proregion or activation peptide that must be removed or rearranged to expose the active site. The process is highly regulated and occurs in diverse physiological contexts, including digestion, blood coagulation, complement activation, apoptosis, and host defense [2,4,7]. Researchers study zymogen activation to understand how proteolytic cascades are initiated and controlled, and how their dysregulation leads to disease [2,7]. For example, caspases are activated from zymogens during apoptosis, and their improper activation contributes to neurodegeneration and cancer [4,7]. Similarly, the complement protease C1r undergoes zymogen activation as part of the classical complement pathway, and blocking this step is a therapeutic strategy. Matriptase, a type II transmembrane serine protease, requires zymogen activation for its roles in epithelial development and cancer progression. Recent structural and biochemical studies have revealed how zymogen activation is triggered by specific proteases, cofactors, or autocatalytic events [1,3]. For instance, the SARS-CoV-2-related coronavirus HKU1 exploits TMPRSS2 zymogen activation for spike protein priming, highlighting the biomedical importance of this process. In horseshoe crabs, a lipopolysaccharide-sensitive zymogen initiates hemolymph coagulation through autocatalytic activation, providing insights into innate immunity. Thus, GO:0031638 encompasses a wide range of proteolytic events that are central to both normal physiology and disease pathogenesis.

Zymogen activation is the proteolytic processing of an inactive enzyme precursor (zymogen) to its active form. This typically involves cleavage of a proregion or activation peptide, which induces conformational changes that expose the catalytic site or allow substrate binding. The process is irreversible and often occurs in cascades, enabling amplification and tight regulation of proteolytic activity.

Zymogen activation is a central regulatory mechanism that prevents unwanted proteolysis while allowing rapid, localized enzyme activation when needed. It is essential for diverse physiological processes such as blood coagulation, complement-mediated immunity, apoptosis, and digestion [2,4,7]. Dysregulation of zymogen activation underlies numerous diseases, including cancer, where proteases like matriptase promote invasion and metastasis, and complement disorders, where C1r activation drives tissue damage. Understanding zymogen activation provides opportunities for therapeutic intervention, as exemplified by inhibitors targeting TMPRSS2 or C1r [1,6].

The following genes encode proteases and regulators that undergo or control zymogen activation, as supported by published literature.

Zymogen activation is regulated by several mechanisms to prevent unwanted proteolysis. Proregions act as intramolecular inhibitors that must be removed or displaced for activity. Activation often requires specific proteases, cofactors, or autocatalytic events that are spatially and temporally controlled [2,3]. For example, C1r activation in the complement system is triggered by C1q binding to immune complexes, and C1 inhibitor rapidly inactivates active C1r. In apoptosis, caspase activation is regulated by inhibitors of apoptosis proteins (IAPs) and by the apoptosome [4,7]. Additionally, pH and ion gradients in organelles such as lysosomes can influence zymogen activation. These regulatory layers ensure that proteolytic activity is confined to appropriate compartments and conditions.

Dysregulated zymogen activation contributes to cancer progression. Matriptase, a serine protease activated from its zymogen, promotes epithelial-to-mesenchymal transition and tumor invasion. Matrix metalloproteinases (MMPs) such as MMP2 and MMP9 are activated from proenzymes and degrade extracellular matrix, facilitating metastasis. Caspase zymogen activation is often evaded in cancer cells, leading to resistance to apoptosis [4,7]. Targeting zymogen activation pathways is a therapeutic strategy in oncology.

The complement system relies on zymogen activation for its effector functions. C1r zymogen activation initiates the classical pathway, and excessive activation leads to tissue damage in autoimmune diseases. Blocking C1r activation is a novel mode of complement inhibition. In pancreatitis, premature activation of trypsinogen within the pancreas causes autodigestion and inflammation. Mutations in PRSS1 that enhance zymogen activation are linked to hereditary pancreatitis.

Caspase zymogen activation is a key executioner of apoptosis in neurons. Aberrant caspase activation contributes to neurodegeneration in conditions such as Alzheimer's and Parkinson's diseases [4,7]. Inhibiting caspase zymogen activation is being explored as a neuroprotective strategy. Additionally, proteases like calpains and cathepsins undergo zymogen activation in lysosomal dysfunction, linking to neurodegenerative storage disorders.

Many pathogens exploit host zymogen activation for entry or immune evasion. The HKU1 coronavirus uses TMPRSS2 zymogen activation to prime its spike protein for membrane fusion. Structural studies of TMPRSS2 zymogen activation provide a basis for designing inhibitors that block viral entry. In horseshoe crabs, a lipopolysaccharide-sensitive zymogen initiates coagulation as part of innate immunity against bacterial infection.

Zymogen activation can be measured using fluorogenic or colorimetric substrates that emit signal upon cleavage by the active enzyme. These assays are used to quantify activation kinetics and inhibitor efficacy [2,4]. For example, caspase activity is commonly measured using Ac-DEVD-AMC.

Activation is often detected by a shift in molecular weight upon cleavage of the proregion. Western blotting with antibodies against the proform and active form can reveal activation status [1,6]. This method is widely used for caspases, complement proteases, and matriptase [4,6,8].

High-resolution structures of zymogens and their active forms reveal conformational changes and cleavage sites. For instance, the structure of TMPRSS2 zymogen and its activation mechanism was elucidated by crystallography. Caspase structures have provided insights into allosteric regulation.

CRISPR knockout, knock-in, and point mutation models are used to study the role of specific genes in zymogen activation. For example, knockout of TMPRSS2 prevents viral spike activation, and point mutations can block cleavage. These models help establish causality.

Researchers studying zymogen activation-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genome editing to create knockout, point mutation, knock-in, or overexpression models. EDITGENE provides end-to-end CRISPR services to accelerate such studies.

Zymogen activation (GO:0031638) is a tightly regulated proteolytic process essential for diverse physiological functions, from digestion and blood coagulation to apoptosis and immunity. Its dysregulation contributes to cancer, inflammatory diseases, and infections, making it a compelling therapeutic target. Advances in structural biology and CRISPR genome editing continue to unravel the molecular details of zymogen activation, offering new opportunities for drug discovery. EDITGENE provides comprehensive CRISPR solutions to accelerate research in this field.